


LA SCELTA DI SPECIE A MINOR IMPATTO

VITTORIA RAFFA DIPARTIMENTO DI BIOLOGIA <u>VITTORIA.RAFFA@UNIPI.IT</u>





DIRECTIVE 2010/63/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 22 SEPTEMBER 2010 ON THE PROTECTION OF ANIMALS USED FOR SCIENTIFIC PURPOSES


- (10) While it is desirable to replace the use of live animals in procedures by other methods not entailing the use of live animals, the use of live animals continues to be necessary to protect human and animal health and the environment.
- (12) Animals have an intrinsic value which must be respected.

DIRECTIVE 2010/63/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 22 SEPTEMBER 2010 ON THE PROTECTION OF ANIMALS USED FOR SCIENTIFIC PURPOSES

 (13) The choice of methods should therefore ensure the selection of the method that is able to provide the most satisfactory results and is likely to cause the minimum pain, suffering or distress. The methods selected should use the minimum number of animals that would provide reliable results and require the use of species with the lowest capacity to experience pain, suffering, distress or lasting harm that are optimal for extrapolation into target species. DIRECTIVE 2010/63/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 22 SEPTEMBER 2010 ON THE PROTECTION OF ANIMALS USED FOR SCIENTIFIC PURPOSES

• (11) When choosing methods, the principles of replacement, reduction and refinement should be implemented through a strict hierarchy of the requirement to use alternative methods. Where no alternative method is recognised by the legislation of the Union, the numbers of animals used may be reduced by resorting to other methods and by implementing testing strategies, such as the use of in vitro and other methods that would reduce and refine the use of animals.

Fig. 1. Regenerative regulation.



Rebecca Robinson Sci Transl Med 2011;3:112fs11

Science Translational Medicine


Copyright © 2011, American Association for the Advancement of Science

IT IS IN SCIENTISTS' INTEREST TO ADOPT AN ETHICAL AND HUMANE APPROACH TO HUSBANDRY AND EXPERIMENTAL DESIGN, AS HEALTHY ANIMALS PRODUCE ROBUST, RELIABLE RESULTS, UNDERLYING VALID SCIENTIFIC OUTPUTS

For example, improved husbandry and handling of rodents reduces stress and this leads to lessvariable data and more meaningful results 10.1136/bmjos-2018-000048

RESEARCH ON ANIMALS IS ONLY ETHICAL IF IT GENERATES VALUE FOR SCIENCE AND SOCIETY


10.1136/bmjos-2018-000048



REPLACING PROTECTED ANIMALS WITH


- COMPUTER MODELLING APPROACHES
- CELL LINES
- PRIMARY CELLS
- TISSUES
- LESS SENTIENT FORMS OR SPECIES


Robustness, scientific validity



education

PRE-CLINICAL RESEARCH









This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 862714.


I-GENE IN-VIVO GENE EDITING BY NANOTRANSDUCERS






A light-activable nanoformulation of Cas9 (PCT/IB2020/050432)








ADVANTAGES OF ZEBRAFISH AS *IN VIVO* ANIMAL MODEL






Zebrafish for gene-editing validation




Images of depigmentation phenotypes of 3dpf zebrafish embryos after editing.



XENOTRAPIANTO DI CELLULE TUMORALI PRIMARIE IN EMBRIONI DI ZEBRAFISH: NUOVO APPROCCIO DI MEDICINA PERSONALIZZATA




MOUSE AVATAR




http://genendesign.com/website/avatar/


20




A MODEL OF A ZEBRAFISH AVATAR FOR CO-CLINICAL TRIALS




TOP: percentage of partial response (PR) and complete response (CR). Zebrafish avatars xenotransplanted with colon tumor (**A**); pancreas (**B**); gastric tumor (**C**). BOTTOM: chemosensitivity assay. Two dpf embryos were injected with fragments of patient tumor tissue and incubated for 48 h with chemotherapy compounds. Representative cases of colon cancer (C024 and C031 patient-derived xenograft (PDX)) and pancreatic cancer (P025 and P030 PDX) with quantitative analysis of the relative tumor area (2 dpi/2 hpi for colon and 2 dpi/1 dpi for pancreas). Mean ± SEM and analyzed by 1-way ANOVA followed by Dunnett's multiple comparisons test. * p < 0.05.







IN VITRO REGENERATION MODEL




Hippocampal neurons




Raffa et al, Nanomedicine 2014 Raffa et al, BiophysJ, 2018




In vitro regeneration model created with IBIDI cell insert







EX-VIVO REGENERATION MODEL



SIGH	IUST R <u>LOSE</u> F OF TH CTIVE		HQ HQ 109.995 0 3					1 1 1 m 0
Posta in arrivo	GRAZIE - Posta in arrivo X					I	- 0	×
🖵 Scarica messaggi 🔽 🖋 Scrivi	🖵 Chat 🖪 Rubrica 🔊 Etichetta 🗸	V Filtro veloce	Cerca <ctrl+k></ctrl+k>				Q] ≡
				✤ Rispondi → Inoltra	Archivia	ð Indesiderata	<u> Elimina</u>	
Oggetto GRAZIE A Me 🗙							06/09/202	0, <mark>1</mark> 2.16
Salve Dott.ssa Raffa, Mi chiamo	, sono un ragazzo di 35 anni che	a causa di un incidente stradale	lo scorso anno, sono stato	costretto a su una sec	lia a rotelle			
Ho letto l'articolo della ricerc	a effettuata presso il suo laborato	rio e ci tenevo a ringrarla insiem	e a tutto il suo staff per il la	voro svolto				

Peripheral Nerve Regeneration





ADVANCED HEALTHCARE **MATERIALS**

Communication 🗎 🖻 Free Access

Magnetic Nanoparticles for Efficient Delivery of Growth Factors: Stimulation of Peripheral Nerve Regeneration

Martina Giannaccini, M. Pilar Calatayud, Andrea Poggetti, Silvia Corbianco, Michela Novelli, Melania Paoli, Pietro Battistini, Maura Castagna, Luciana Dente, Paolo Parchi, Michele Lisanti, Gabriella Cavallini , Concepción Junquera, Gerardo F. Goya, Vittoria Raffa 🗙

Median nerve

Sciatic nerve

